Welcome to our dedicated page for Neuronetics SEC filings (Ticker: STIM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Neuronetics, Inc. (NASDAQ: STIM) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Neuronetics is a commercial stage medical technology and healthcare company focused on NeuroStar Advanced Therapy, a non-drug, noninvasive transcranial magnetic stimulation (TMS) treatment, and on operating Greenbrook TMS treatment centers across the United States. Its filings offer detailed insight into how this device-and-clinic model is reflected in reported revenues, capital structure, and risk disclosures.
Among the most relevant documents for STIM are current reports on Form 8-K, which Neuronetics uses to announce quarterly financial and operating results, amendments to its credit agreement with Perceptive Credit Holdings IV, LP, and other material events. These filings confirm that the company’s common stock is listed on The Nasdaq Global Market and provide information on revenue by geography and product category, including NeuroStar system sales, treatment sessions, and U.S. clinic revenue from Greenbrook centers. Form 8-Ks also describe leadership changes, such as the appointment of a new Chief Financial Officer and a planned CEO retirement, and summarize key terms of executive employment and compensation arrangements.
Investors reviewing Neuronetics’ filings can also examine disclosures about its credit facility, including additional borrowing tranches, minimum liquidity requirements, and associated warrant issuances. Safe harbor statements in these reports outline forward-looking risks related to reliance on NeuroStar Advanced Therapy System sales and usage, payer coverage and reimbursement for TMS treatments, competition from other technologies, and the integration of Greenbrook’s clinic business.
On Stock Titan, these SEC filings are complemented by AI-powered summaries that highlight the main points of lengthy documents such as 10-K annual reports, 10-Q quarterly reports, and 8-K current reports. Users can quickly see how Neuronetics presents its business model, revenue drivers, and risk factors, and can also track insider and equity-related activity through filings that describe inducement equity awards and warrant issuances. Real-time updates from EDGAR ensure that new Neuronetics filings, including financial results and material agreements, are available promptly with simplified explanations for faster analysis.
Neuronetics, Inc. insider activity: 10% owner Jorey Chernett purchased 169,472 shares of Neuronetics common stock in an open-market transaction at a weighted average price of $1.41 per share. The footnote states the trades occurred in multiple transactions between $1.36 and $1.44 per share, rounded to the nearest cent.
Following this purchase, Chernett directly holds 8,743,276 Neuronetics shares. The filing notes he can provide detailed breakdowns of the number of shares bought at each specific price upon request by the company, its security holders, or the SEC staff.
Neuronetics, Inc. 10% owner Jorey Chernett reported significant open-market buying of the company’s common stock. On March 18, 2026, he purchased 607,400 shares at a weighted average price of $1.35 per share in multiple trades. On March 19, 2026, he bought an additional 450,000 shares at a weighted average price of $1.33 per share, also across multiple transactions. Following these purchases, Chernett directly owns 8,573,804 shares of Neuronetics common stock.
STIM submitted a Form 144 notice to sell 16,005 shares of Common Stock tied to Restricted Stock Vesting with an effective date of 12/31/2025.
The filing also discloses recent dispositions by William A. Macan: 3,485 shares on 02/10/2026, 14,120 shares on 02/12/2026, 3,427 shares on 02/26/2026, and 609 shares on 03/04/2026.
STIM submitted a Form 144 notice reporting a proposed sale of Common stock associated with a restricted stock vesting event. The filing lists 46,289 shares tied to 03/18/2026 as the securities to be sold. The filing also discloses recent dispositions by Keith Sullivan of 40,976, 33,847, and 8,452 shares on 02/10/2026, 02/12/2026, and 02/26/2026, respectively.
Sullivan Keith J reported acquisition or exercise transactions in this Form 4 filing.
Neuronetics, Inc. reported that President and CEO Keith J. Sullivan received a grant of 112,500 shares of common stock. The shares were issued for no cash consideration upon satisfaction of performance criteria tied to performance-based restricted stock units. Following this award, Sullivan directly holds 1,637,213 shares of Neuronetics common stock. This is a compensation-related equity award rather than an open-market purchase.
Neuronetics, Inc. reported that its EVP, CLO and CS, William Andrew Macan, received an award of 33,750 shares of common stock. These shares were granted for no cash consideration after performance criteria tied to performance-based restricted stock units were satisfied. Following this equity award, his directly held common stock position increased to 913,275 shares, highlighting a compensation-related, non-market acquisition rather than an open-market purchase.
Pfanstiel Steven reported acquisition or exercise transactions in this Form 4 filing.
Neuronetics, Inc. reported that EVP, CFO and Treasurer Steven Pfanstiel received an equity grant of 25,000 restricted stock units (RSUs). Each RSU represents a right to receive one share of common stock, vesting in three equal annual installments beginning on March 17, 2027, subject to his continuous service. Following this award, Pfanstiel is shown as holding 845,212 shares of common stock directly.
Neuronetics, Inc. major shareholder Jorey Chernett reported an open-market purchase of 531,000 shares of common stock at a weighted average price of $1.16 per share. The filing notes the shares were bought in multiple trades between $0.91 and $1.31 per share. Following this transaction, Chernett directly owns 7,516,404 shares of Neuronetics common stock.
Neuronetics, Inc. reported that significant shareholder Jorey Chernett beneficially owns 6,985,404 shares of the company’s common stock. This Form 3 filing is an initial statement of holdings by a more than ten percent owner and does not reflect any new share transactions.
Neuronetics, Inc. filing amends beneficial ownership disclosure for Jorey Chernett. As of the close of business on March 17, 2026, the Reporting Person beneficially owned 7,516,404 shares of Common Stock, representing 10.85% of the class based on 69,276,593 Shares outstanding as of March 10, 2026.
The amendment updates the Schedule 13G/A ownership figures and reports sole voting and dispositive power over the disclosed shares. The statement is signed and dated 03/18/2026.